The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer

Daisuke Imai, Tomoharu Yoshizumi, Shinji Okano, Hideaki Uchiyama, Toru Ikegami, Norifumi Harimoto, Shinji Itoh, Yuji Soejima, Shinichi Aishima, Yoshinao Oda, Yoshihiko Maehara

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDA) is associated with an immunosuppressive tumor-microenvironment (TME) that supports the growth of tumors and mediates tumors enabling evasion of the immune system. Expression of programmed cell death ligand 1 (PD-L1) and loss of human leukocyte antigen (HLA) class I on tumor cells are methods by which tumors escape immunosurveillance. We examined immune cell infiltration, the expression of PD-L1 and HLA class I by PDA cells, and the correlation between these immunological factors and clinical prognosis. PDA samples from 36 patients were analyzed for HLA class I, HLA-DR, PD-L1, PD-1, CD4, CD8, CD56, CD68, and FoxP3 expression by immunohistochemistry. The correlations between the expression of HLA class I, HLA-DR, PD-L1 or PD-1 and the pattern of tumor infiltrating immune cells or the patients’ prognosis were assessed. PD-L1 expression correlated with tumor infiltration by CD68+ and FoxP3+ cells. Low HLA class I expression was an only risk factor for poor survival. PD-L1 negative and HLA class I high-expressing PDA was significantly associated with higher numbers of infiltrating CD8+ T cells in the TME, and a better prognosis. Evaluation of both PD-L1 and HLA class I expression by PDA may be a good predictor of prognosis for patients. HLA class I expression by tumor cells should be evaluated when selecting PDA patients who may be eligible for treatment with PD-1/PD-L1 immune checkpoint blockade therapies.

Original languageEnglish
Pages (from-to)1614-1626
Number of pages13
JournalCancer Medicine
Volume6
Issue number7
DOIs
Publication statusPublished - Jul 2017

Fingerprint

HLA Antigens
Pancreatic Neoplasms
Cell Death
Ligands
Adenocarcinoma
CD274 Antigen
Neoplasms
Tumor Microenvironment
Tumor Escape
Immunologic Monitoring
Immunologic Factors
Immunosuppressive Agents
Immune System
Immunohistochemistry
T-Lymphocytes
Survival
Therapeutics
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. / Imai, Daisuke; Yoshizumi, Tomoharu; Okano, Shinji; Uchiyama, Hideaki; Ikegami, Toru; Harimoto, Norifumi; Itoh, Shinji; Soejima, Yuji; Aishima, Shinichi; Oda, Yoshinao; Maehara, Yoshihiko.

In: Cancer Medicine, Vol. 6, No. 7, 07.2017, p. 1614-1626.

Research output: Contribution to journalArticle

Imai, Daisuke ; Yoshizumi, Tomoharu ; Okano, Shinji ; Uchiyama, Hideaki ; Ikegami, Toru ; Harimoto, Norifumi ; Itoh, Shinji ; Soejima, Yuji ; Aishima, Shinichi ; Oda, Yoshinao ; Maehara, Yoshihiko. / The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. In: Cancer Medicine. 2017 ; Vol. 6, No. 7. pp. 1614-1626.
@article{ef767616e63e44b8966fc23de8ab0974,
title = "The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer",
abstract = "Pancreatic ductal adenocarcinoma (PDA) is associated with an immunosuppressive tumor-microenvironment (TME) that supports the growth of tumors and mediates tumors enabling evasion of the immune system. Expression of programmed cell death ligand 1 (PD-L1) and loss of human leukocyte antigen (HLA) class I on tumor cells are methods by which tumors escape immunosurveillance. We examined immune cell infiltration, the expression of PD-L1 and HLA class I by PDA cells, and the correlation between these immunological factors and clinical prognosis. PDA samples from 36 patients were analyzed for HLA class I, HLA-DR, PD-L1, PD-1, CD4, CD8, CD56, CD68, and FoxP3 expression by immunohistochemistry. The correlations between the expression of HLA class I, HLA-DR, PD-L1 or PD-1 and the pattern of tumor infiltrating immune cells or the patients’ prognosis were assessed. PD-L1 expression correlated with tumor infiltration by CD68+ and FoxP3+ cells. Low HLA class I expression was an only risk factor for poor survival. PD-L1 negative and HLA class I high-expressing PDA was significantly associated with higher numbers of infiltrating CD8+ T cells in the TME, and a better prognosis. Evaluation of both PD-L1 and HLA class I expression by PDA may be a good predictor of prognosis for patients. HLA class I expression by tumor cells should be evaluated when selecting PDA patients who may be eligible for treatment with PD-1/PD-L1 immune checkpoint blockade therapies.",
author = "Daisuke Imai and Tomoharu Yoshizumi and Shinji Okano and Hideaki Uchiyama and Toru Ikegami and Norifumi Harimoto and Shinji Itoh and Yuji Soejima and Shinichi Aishima and Yoshinao Oda and Yoshihiko Maehara",
year = "2017",
month = "7",
doi = "10.1002/cam4.1087",
language = "English",
volume = "6",
pages = "1614--1626",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer

AU - Imai, Daisuke

AU - Yoshizumi, Tomoharu

AU - Okano, Shinji

AU - Uchiyama, Hideaki

AU - Ikegami, Toru

AU - Harimoto, Norifumi

AU - Itoh, Shinji

AU - Soejima, Yuji

AU - Aishima, Shinichi

AU - Oda, Yoshinao

AU - Maehara, Yoshihiko

PY - 2017/7

Y1 - 2017/7

N2 - Pancreatic ductal adenocarcinoma (PDA) is associated with an immunosuppressive tumor-microenvironment (TME) that supports the growth of tumors and mediates tumors enabling evasion of the immune system. Expression of programmed cell death ligand 1 (PD-L1) and loss of human leukocyte antigen (HLA) class I on tumor cells are methods by which tumors escape immunosurveillance. We examined immune cell infiltration, the expression of PD-L1 and HLA class I by PDA cells, and the correlation between these immunological factors and clinical prognosis. PDA samples from 36 patients were analyzed for HLA class I, HLA-DR, PD-L1, PD-1, CD4, CD8, CD56, CD68, and FoxP3 expression by immunohistochemistry. The correlations between the expression of HLA class I, HLA-DR, PD-L1 or PD-1 and the pattern of tumor infiltrating immune cells or the patients’ prognosis were assessed. PD-L1 expression correlated with tumor infiltration by CD68+ and FoxP3+ cells. Low HLA class I expression was an only risk factor for poor survival. PD-L1 negative and HLA class I high-expressing PDA was significantly associated with higher numbers of infiltrating CD8+ T cells in the TME, and a better prognosis. Evaluation of both PD-L1 and HLA class I expression by PDA may be a good predictor of prognosis for patients. HLA class I expression by tumor cells should be evaluated when selecting PDA patients who may be eligible for treatment with PD-1/PD-L1 immune checkpoint blockade therapies.

AB - Pancreatic ductal adenocarcinoma (PDA) is associated with an immunosuppressive tumor-microenvironment (TME) that supports the growth of tumors and mediates tumors enabling evasion of the immune system. Expression of programmed cell death ligand 1 (PD-L1) and loss of human leukocyte antigen (HLA) class I on tumor cells are methods by which tumors escape immunosurveillance. We examined immune cell infiltration, the expression of PD-L1 and HLA class I by PDA cells, and the correlation between these immunological factors and clinical prognosis. PDA samples from 36 patients were analyzed for HLA class I, HLA-DR, PD-L1, PD-1, CD4, CD8, CD56, CD68, and FoxP3 expression by immunohistochemistry. The correlations between the expression of HLA class I, HLA-DR, PD-L1 or PD-1 and the pattern of tumor infiltrating immune cells or the patients’ prognosis were assessed. PD-L1 expression correlated with tumor infiltration by CD68+ and FoxP3+ cells. Low HLA class I expression was an only risk factor for poor survival. PD-L1 negative and HLA class I high-expressing PDA was significantly associated with higher numbers of infiltrating CD8+ T cells in the TME, and a better prognosis. Evaluation of both PD-L1 and HLA class I expression by PDA may be a good predictor of prognosis for patients. HLA class I expression by tumor cells should be evaluated when selecting PDA patients who may be eligible for treatment with PD-1/PD-L1 immune checkpoint blockade therapies.

UR - http://www.scopus.com/inward/record.url?scp=85020379200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020379200&partnerID=8YFLogxK

U2 - 10.1002/cam4.1087

DO - 10.1002/cam4.1087

M3 - Article

C2 - 28602029

AN - SCOPUS:85020379200

VL - 6

SP - 1614

EP - 1626

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 7

ER -